BioWorld Asia

Oct. 1, 2008

Nitec Pharma Gets $22M to Fund Lodotra Launch

With a first European approval for its rheumatoid arthritis drug Lodotra imminent, Nitec Pharma AG raised CHF24 million (US$22 million) in a private equity round led by Munich, Germany-based TVM Capital. (BioWorld International) Read More

Telormedix Gets $19M in Series A Round

Elucidation of Cancer Growth Yields Potential Drug Targets

Nextech Closes Oncology Fund with $65M in Hand

Phynova Focusing on China, Pipeline and Conserving Cash

Genetically Modified Cotton is Good Neighbor to Other Crops

NicOx Signs Naproxcinod Agreement with Capsugel

ExonHit Therapeutics to Provide Genomic Services to French CRO

FDA Investigating Deaths in Ortho's German Stroke Trial

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for July 24, 2026.

To viral or not to viral: In vivo CAR T debates delivery tech

BioWorld

The field of cell and gene therapy is moving toward a new phase of scalability and clinical durability, with in vivo chimeric antigen receptor (CAR) T-cell...

News in brief

BioWorld Asia

BioWorld Asia briefs for July 21, 2026

Tree in the shape of human head losing leaves

KBN-2201 reverses key features of Alzheimer’s in mice

BioWorld Science

Researchers from Ajou University School of Medicine reported the preclinical efficacy of KBN-2201 in a mouse model of late-stage Alzheimer’s disease.

Click chemistry drug bound to pancreatic cancer cells from mice

In vivo click ADCs could address tumor heterogeneity

BioWorld

Researchers at Washington University in St. Louis have used click chemistry to link a second antibody to a pre-existing antibody-drug conjugate (ADC) in vivo. In...